Khiron Life Sciences (Khiron Life Sciences) Change In Working Capital : $-0.31 Mil (TTM As of Sep. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Khiron Life Sciences Change In Working Capital?

Khiron Life Sciences's change in working capital for the quarter that ended in Sep. 2022 was $-1.52 Mil.

Khiron Life Sciences's change in working capital for the fiscal year that ended in Dec. 2021 was $-1.82 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Khiron Life Sciences Change In Working Capital Historical Data

The historical data trend for Khiron Life Sciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Change In Working Capital Chart

Khiron Life Sciences Annual Data

Trend

May12

May13

May14

May15

May16

May17

Dec18

Dec19

Dec20

Dec21

Change In Working Capital

Get a 7-Day Free Trial

0.02

0.99

-2.42

-1.51

-1.82

Khiron Life Sciences Quarterly Data
	Nov17	Feb18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Working Capital	Get a 7-Day Free Trial															-0.82	0.15	0.28	0.78	-1.52

Khiron Life Sciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Khiron Life Sciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Khiron Life Sciences (Khiron Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRNF) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5

Website

https://www.khiron.ca

Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.